<DOC>
	<DOCNO>NCT02431559</DOCNO>
	<brief_summary>This open-label , non‐randomized , multicenter Phase 1/2 study MEDI4736 subject recurrent , platinum-resistant ovarian cancer , schedule receive Pegylated Liposomal Doxorubicin ( PLD ) . Subjects treat 28-day cycle accord treatment schedule .</brief_summary>
	<brief_title>A Phase 1/2 Study Motolimod ( VTX-2337 ) MEDI4736 Subjects With Recurrent , Platinum-Resistant Ovarian Cancer Whom Pegylated Liposomal Doxorubicin ( PLD ) Indicated</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects must recurrent persistent platinumresistant epithelial ovarian , fallopian tube , primary peritoneal carcinoma measureable disease ( defined RECIST 1.1 . ) first second line platinumbased chemotherapy , treatment PLD indicate . Platinumbased therapy define treatment carboplatin , cisplatin another organoplatinum compound . Platinumresistant define platinumfree interval ( PFI ) &lt; 12 month first secondline platinumbased chemotherapy , disease progression receive secondline platinumbased chemotherapy . Subjects allow receive , require receive : one additional cytotoxic regimen and/or PARP inhibitor management recurrent persistent disease . biologic therapy ( e.g. , bevacizumab ) part primary treatment regimen part treatment management recurrent persistent disease . 2 . Histologic documentation original primary tumor . 3 . Documented radiographic disease progression &lt; 12 month last dose first secondline platinumbased chemotherapy . 4 . Subjects Phase 2 must disease amenable biopsy must willing undergo pre posttreatment tumor biopsy . Optional Phase 1 . Note : archival tissue request subject preferably primary tumor site prior cancer treatment ; however , archival tissue requirement study entry . 5 . ECOG performance status 0 1 . 6 . Laboratory parameter vital function normal range . Laboratory abnormality clinically significant generally permit , except follow laboratory parameter , must within range specify , regardless clinical significance : Hemoglobin : ≥ 9 g/dL Neutrophil count : ≥ 1.5 x 109/L Platelet count : ≥ 100,000/mm3 Serum creatinine , ≤ 1.5x Institutional Upper Limit Normal ( ULN ) , Creatinine Clearance ≥ 50 mL/min ( CockcroftGault formula ) Serum bilirubin : ≤ 1.2 mg/dL AST/ALT : ≤ 2.5 x ULN Alkaline phosphatase : ≤ 2.5 x ULN 7 . Age ≥18 year . 8 . Able willing give valid write informed consent . 9 . Body weight &gt; 30 kg 1 . Prior exposure doxorubicin , PLD anthracycline , motolimod TLR agonist , MEDI4736 checkpoint inhibitor , antiCTLA4 antiPD1/antiPDL1 antibody . 2 . Subjects platinumrefractory disease , define disease progression receive first line platinumbased therapy . 3 . Clinically significant persistent immunerelated adverse event follow prior therapy . 4 . Subjects history evidence upon physical examination CNS disease , include primary brain tumor , seizures control standard medical therapy , brain metastasis , , within six month prior Day 1 study , history cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) subarachnoid hemorrhage . 5 . Subjects clinically significant cardiovascular disease . This include : 1 . Resisted hypertension 2 . Myocardial infarction unstable angina within 6 month prior Day 1 study . 3 . History serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ) cardiac arrhythmia require antiarrhythmic medication , except atrial fibrillation well control antiarrhythmic medication . 4 . Baseline ejection fraction ≤ 50 % assessed echocardiogram MUGA . 5 . New York Heart Association ( NYHA ) Class II higher congestive heart failure . 6 . Grade 2 high peripheral ischemia , except brief ( &lt; 24 hr ) episodes ischemia manage nonsurgically without permanent deficit . 6 . History pneumonitis interstitial lung disease . 7 . Active , suspect prior document autoimmune disease ( include inflammatory bowel disease , celiac disease , Wegner 's granulomatosis , active Hashimoto 's thyroiditis , rheumatoid arthritis , lupus , scleroderma variant , multiple sclerosis , myasthenia gravis ) . Vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger permit . 8 . Other malignancy within 2 year prior Day 1 study , except treated surgical intervention . 9 . Subjects clinical symptom sign gastrointestinal obstruction and/or require drainage gastrostomy tube and/or parenteral hydration nutrition . 10 . Known immunodeficiency HIV , Hepatitis B Hepatitis C positivity . 11 . History severe allergic reaction unknown allergen component study drug . 12 . Other serious illness ( e.g. , serious infection require antibiotic , bleed disorder ) . 13 . Prior treatment interventional clinical trial within 4 week prior Day 1 study . 14 . Mental impairment may compromise compliance requirement study . 15 . Lack availability immunological clinical followup assessment . 16 . Women breastfeed pregnant evidence positive serum pregnancy test 17 . Subjects unwilling use acceptable method contraception . Female subject refrain breastfeed throughout period . 18 . Any condition , clinical judgment treat physician , likely prevent subject comply aspect protocol may put subject unacceptable risk . 19 . Subjects must donate blood study least 90 day follow last MEDI4736 treatment . 20 . History allogeneic organ transplant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Motolimod</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>PD-L1</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Pegylated</keyword>
	<keyword>Liposomal</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>PLD</keyword>
	<keyword>TLR-8</keyword>
	<keyword>Durvalumab</keyword>
</DOC>